Skip to content
Screener

Bausch Health Companies BHC Financing Cash Flow

Financing Cash Flow at other companies

Bausch + Lomb logo
Bausch + LombBLCO
$34M-62.2%
Johnson & Johnson logo
Johnson & JohnsonJNJ
-$8.78B-54.9%
Staar Surgical logo
Staar SurgicalSTAA
-$1.69M-78.6%
Apyx Medical Corporation logo
Apyx Medical CorporationAPYX
$83K+232%
Ardelyx logo
ArdelyxARDX
$49.72M+0.1%
Ironwood Pharmaceuticals logo
Ironwood PharmaceuticalsIRWD
$122K+101%

Other financials

Income statement

See full
Revenue$2.5B+11.7%
Operating income-$950.0M-444%
Net income-$1.4B-2,353%
EPS (diluted)-$3.82-2,287%

Balance sheet

See full
Cash & equivalents$1.3B+13.4%
Total debt$20.8B-3.5%
Total equity-$2.1B-74.0%
Total assets$24.5B-7.3%

Cash flow

See full
Operating cash flow$230.0M+9.0%
CapEx$109.0M-5.2%
Free cash flow$121.0M+26.0%

Valuation

See full
Market cap$2.34B+11.7%
Enterprise value$21.79B-1.3%
P/S0.2×0.0×

Profitability

See full
Gross margin71.4%
Operating margin5.6%-10.3pp
Net margin-1.9%-0.9pp
FCF margin9.8%-2.8pp

Returns & leverage

See full
Return on equity-70.1%
Debt / equity45.2×
Current ratio1.3×0.0×

Where this comes from

Reported directly by Bausch Health Companies in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Bausch Health Companies’s 10-Q, filed April 30, 2026.

Filed
Apr 29, 2026, 6:12 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0000885590-26-000053
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Payments of acquisition-related contingent consideration(8)(7)
Payments of financing costs(1)(5)
Other(2)
Net cash used in financing activities(100)(146)
Effect of exchange rate changes on cash, cash equivalents and restricted cash(4)21
Net decrease in cash, cash equivalents and restricted cash(13)(44)
Cash, cash equivalents and restricted cash, beginning of period1,3251,201
Cash, cash equivalents and restricted cash, end of period$1,312$1,157

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Bausch Health Companies's financing cash flow?
Bausch Health Companies (BHC) reported financing cash flow of -$100M in Q1 2026.
How has Bausch Health Companies's financing cash flow changed year-over-year?
Bausch Health Companies's financing cash flow increased by 31.5% year-over-year, from -$146M to -$100M.
What is the long-term trend for Bausch Health Companies's financing cash flow?
Over 3 years (2022 to 2025), Bausch Health Companies's financing cash flow has grown at a 16.1% compound annual growth rate (CAGR), from -$474M to -$742M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Bausch Health Companies's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude